October 2013

A review of the ACCOAST, ASSURE, Edoxaban Hokusai-VTE, EXAMINE, PRAMI, RE-ALIGN, and SAVOR-TIMI 53, and TAO studies presented at the European Society of Cardiology 2013 Congress.

Aparna M. Bhagavat, MD, FACC, says gliptins have a promising role in the control of type 2 diabetes, as they decrease A1C without hypoglycemia, weight gain, or any obvious adverse effects on cardiovascular outcomes.

Rabab Mohsin, MD, reviews adverse outcomes among women from the Women's Ischemia Syndrome Evaluation (WISE) study.

Have the Appropriate Use Criteria for transthoracic echocardiography achieved their goal of having a significant clinical impact on physician decision making?